NEW YORK (GenomeWeb News) – Physician's Choice Laboratory Services today announced a partnership to offer Genesys Biolabs' proteomic test for screening and the early detection of lung cancer.

The test, called PAULA's Test, short for Protein Assay Using Lung Cancer Analytes, measures three tumor proteins and an additional analyte that are commonly associated with lung cancer. The blood-based test is analyzed in Genesys' CLIA-certified laboratory.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.